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ichard D. Patten, MD
oston, Massachusetts
eart transplantation offers a means to improve longevity
nd quality of life in patients with end stage heart failure.
lthough survival following cardiac transplantation im-
roved significantly following the advent of calcineurin
nhibitors, the development of vascular disease within the
rterial system of the grafted heart, known as cardiac
llograft vasculopathy, is a major cause of morbidity and
ortality (1,2). Graft vasculopathy, defined by an angio-
raphically determined stenosis 50% in an epicardial
oronary artery, is present in 40% to 50% of patients by
years post-transplant and is the leading cause of death
n recipients who survive past the first year (3,4). Unfor-
unately, ischemic symptoms in cardiac transplant pa-
ients are often nonspecific, and a common presentation
f cardiac allograft vasculopathy is that of sudden cardiac
eath. Indeed, far too often, transplant cardiologists
eceive the most dreaded of phone calls from a bereaved
pouse, child, or parent reporting the sudden death of a
ransplant recipient. Any modality that can increase our
wareness of patients at high risk for developing progres-
ive graft vasculopathy would be a welcome addition to
he available tools for monitoring patients after cardiac
ransplant.
See page 1279
In this issue of the Journal, Raichlin et al. (5) of the
ayo Clinic explore the utility of virtual histology
ntravascular ultrasound (VH-IVUS) to carefully examine
oronary lesion morphology of transplant recipients and
dentify which type of coronary lesions may predict
rogression of allograft vascular disease. They examined
he frequency and significance of coronary plaques con-
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.a
From the Heart Failure and Cardiac Transplant Program, Tufts Medical Center,
oston, Massachusetts.aining both necrotic core and calcification from VH-
VUS exams performed a mean of 3.6 years following
ransplant in 86 recipients. A subgroup of patients (n 
8) had a follow-up study after 12 months to explore the
ate of progression of these necrotic core/dense calcium
ontaining lesions. The investigators defined “noninflam-
atory” plaque as being composed of 30% by volume of
he combination of both necrotic core and calcium and
inflammatory” plaque as that composed of 30% ne-
rotic core and calcium. They first compared these data to
he total rejection score defined as the average rejection
core of biopsies over 6 months using the revised histo-
ogic grading scheme. They observed more inflammatory
laques in patients with a total rejection score 0.3 than
n those with a total rejection score 0.3, supporting the
dea that early rejection may contribute to inflammatory
laque development. In patients having inflammatory
laque identified in the initial study, there was a signif-
cant increase in plaque volume over 1 year compared
ith those without inflammatory plaque at the initial
H-IVUS examination. The investigators concluded that
his coronary imaging modality may hold promise in
dentifying transplant patients who are at high risk of
eveloping progressive graft vasculopathy.
This retrospective analysis of compiled VH-IVUS (see
eview in Sangiorgi et al. [6]) as a tool to predict
rogression of graft vascular disease has inherent weak-
esses that the investigators emphasize in the discussion.
he rather arbitrary cutoff of 30% for plaque content of
ombined necrotic core and calcium to define an inflam-
atory plaque is based on prior autopsy data from
ontransplanted hearts with coronary artery disease and
ot from coronaries of transplanted hearts. Given the
ifferences in pathophysiology between allograft vascu-
opathy and atherosclerosis, it remains unclear that this
H-IVUS morphology represents inflammation. A data-
et obtained in transplanted hearts at autopsy would be
equired to explore this further. Inherent in this retro-
pective analysis is the significant variability with which
he timing of VH-IVUS was performed following trans-
lantation. Nonetheless, data obtained by VH-IVUS
resented by Raichlin et al. (5) represent a novel and
otentially important approach for the early identifica-
ion of patients at risk of developing graft vasculopathy.
Nearly all patients after cardiac transplant are treated with
-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhib-
tors, antihypertensive medications, and aggressive diabetes
ontrol to combat treatable coronary artery disease risk
actors. More recently, the addition of rapamycin to the
mmunosuppressive regimen of transplant recipients diag-
osed with graft vasculopathy has been shown to stabilize
he progression of vascular disease in many patients (7,8).
hus, in appropriately selected transplant recipients, the
dentification of high-risk coronary morphology might be
n impetus to use earlier, more potent antiproliferative
t
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Risk of Cardiac Allograft Vasculopathy April 14, 2009:1287–8herapy such as rapamycin. Ultimately, earlier intervention may
ead to improved survival in allograft vasculopathy patients.
How this new imaging technology compares with stand-
lone IVUS is not known. A multicenter consortium (9)
erformed IVUS at baseline in the early period following
eart transplantation (4 to 6 weeks) with a repeat IVUS
xam 1 year later. Kobashigawa et al. (9) reported that
atients whose maximal intimal thickness increased 0.5
m over the first 12 months had a markedly higher
ortality and graft loss than those whose maximal intimal
hickness increased 0.5 mm. Moreover, patients with
reater maximal intimal thickness increases had double the
ncidence of angiographically determined graft vasculopathy
t 5 years (65% vs. 32%).
Before any striking conclusions can be drawn from the
ata presented in this novel study by Raichlin et al. (5),
ore clinical data must be collected to help strengthen (or
efute) these preliminary observations. The most rapid
eans of gathering such data would be in the formation of
multicenter consortium to collect data prospectively and
ompare the predictive utility and prognostic value of
ntravascular ultrasound versus VH-IVUS from consistently
imed, consecutive examinations following cardiac trans-
lantation. These data may contribute importantly to our
nderstanding of the pathophysiology underlying this pro-
ressive vasculopathy in cardiac transplant recipients. More-
ver, with these data in hand, it may then be feasible to draw
ore definitive conclusions about the ability of this new
echnology to predict patients at risk of developing cardiac
llograft vasculopathy. veprint requests and correspondence: Dr. Richard D. Patten,
ardiomyopathy Program, New England Heart Institute, Catho-
ic Medical Center, 100 McGregor Street, Manchester, New
ampshire 03102. E-mail: rpatten@CMC-NH.org.
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